Pharvaris (PHVS) Competitors

Praxis Precision Medicines' return on equity of -34.15% beat Pharvaris' return on equity.

Praxis Precision Medicines presently has a consensus target price of $612.42, indicating a potential upside of 115.98%. Pharvaris has a consensus target price of $59.87, indicating a potential upside of 96.35%. Given Praxis Precision Medicines' stronger consensus rating and higher possible upside, research analysts clearly believe Praxis Precision Medicines is more favorable than Pharvaris.

67.8% of Praxis Precision Medicines shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Praxis Precision Medicines has a beta of 2.79, indicating that its stock price is 179% more volatile than the broader market. Comparatively, Pharvaris has a beta of -2.46, indicating that its stock price is 346% less volatile than the broader market.

Pharvaris has lower revenue, but higher earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

In the previous week, Pharvaris had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 5 mentions for Pharvaris and 3 mentions for Praxis Precision Medicines. Pharvaris' average media sentiment score of 0.92 beat Praxis Precision Medicines' score of 0.00 indicating that Pharvaris is being referred to more favorably in the news media.

Pharvaris currently has a consensus price target of $59.87, suggesting a potential upside of 96.35%. Ionis Pharmaceuticals has a consensus price target of $89.20, suggesting a potential upside of 105.06%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Pharvaris.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Pharvaris and Pharvaris both had 5 articles in the media. Pharvaris' average media sentiment score of 0.92 beat Ionis Pharmaceuticals' score of 0.20 indicating that Pharvaris is being referred to more favorably in the media.

Pharvaris has a beta of -2.46, indicating that its share price is 346% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Pharvaris has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Pharvaris has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -64.76%. Pharvaris' return on equity of -61.40% beat Ionis Pharmaceuticals' return on equity.

Pharvaris presently has a consensus target price of $59.87, suggesting a potential upside of 96.35%. Spyre Therapeutics has a consensus target price of $109.71, suggesting a potential upside of 18.33%. Given Pharvaris' higher probable upside, equities analysts plainly believe Pharvaris is more favorable than Spyre Therapeutics.

80.4% of Spyre Therapeutics shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Pharvaris has a beta of -2.46, indicating that its stock price is 346% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.1, indicating that its stock price is 210% more volatile than the broader market.

In the previous week, Spyre Therapeutics had 24 more articles in the media than Pharvaris. MarketBeat recorded 29 mentions for Spyre Therapeutics and 5 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.92 beat Spyre Therapeutics' score of 0.31 indicating that Pharvaris is being referred to more favorably in the media.

Spyre Therapeutics' return on equity of -30.74% beat Pharvaris' return on equity.

Spyre Therapeutics has higher revenue and earnings than Pharvaris. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

47.1% of Immunovant shares are owned by institutional investors. 1.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Immunovant had 1 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Immunovant and 5 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.92 beat Immunovant's score of 0.20 indicating that Pharvaris is being referred to more favorably in the media.

Immunovant is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Pharvaris presently has a consensus price target of $59.87, suggesting a potential upside of 96.35%. Immunovant has a consensus price target of $44.00, suggesting a potential upside of 32.33%. Given Pharvaris' stronger consensus rating and higher possible upside, equities research analysts clearly believe Pharvaris is more favorable than Immunovant.

Pharvaris has a beta of -2.46, indicating that its share price is 346% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Pharvaris' return on equity of -61.40% beat Immunovant's return on equity.